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Familial Amyloid Polyneuropathy (FAP ATTRV30M) is an autosomal dominant 
systemic amyloidosis caused by a point mutation in TTR gene (chr18q12.1) that is 
characterized by deposition of amyloid substance. Until now more than 100 mutations 
in TTR gene have been described, and the most frequent disease causing variant in 
Portugal is the V30M. FAP ATTRV30M shows a wide variation in age-at-onset (AO) 
[19-82 years], in the Portuguese population. Within some families, offspring often 
exhibit anticipation in AO when compared to their parents.  
However, V30M alone does not explain the AO variability of the disease 
observed in the same family. Previous studies in Drosophila expressing TTRV30M 
demonstrated that RAC1 may be associated with phenotypic variability and therefore 
may be a good candidate gene for the study of AO variation in FAP ATTRV30M 
patients. In addition, previous findings in a Cypriot population for C1QA and C1QC 
showed an association of these genes with AO.  Our aim was to unravel if these 
candidate genes associated with TTR pathways may act as genetic modifiers of AO in 
FAP ATTRV30M, studying for the first time the RAC1 gene as a genetic modifier and to 
assess the involvement of C1Q complement genes in order to confirm if the same 
happens in our population.   
We analyzed 267 patients from 117 families. To search for variants in the three 
genes, all exons and flanking regions were genotyped by automatic bidirectional 
sequencing. To account for non-independency of AO between members of the same 
family, we used generalized estimating equations (GEEs) with IBM SPSS software. 
Afterwards, an intensive in silico analysis was performed, in order to predict differences 
in regulation of gene expression and to analyze a putative gene-gene interaction. 
Our results showed that some variants in RAC1, C1QA and C1QC genes were 
associated with late-onset and they can have a protective role in FAP ATTRV30M 
patients. On the other hand, most variants were found to be associated with an early-
onset acting as risk factors for FAP ATTRV30M carriers in RAC1 and in C1QC gene).  
Importantly, we found some interesting results in the in silico analysis, since we found 
some unreported modifications in transcription factors binding and miRNAs binding 
(RAC1 and C1QC genes) and in the mechanism of splicing (C1QA gene).  
 Noteworthy, a strong interaction between C1QA and C1QC genes was found 
showing that these two genes may act together as genetic modifiers. With this study, 
we confirmed the role of C1Q complement genes in FAP Portuguese patients and we 
revealed for the first time the role of RAC1 gene as a genetic modifier of AO variability. 
Importantly, we found very interesting and unreported results in the in silico analysis 
since alterations in these mechanisms can lead to dysregulation of gene expression, 
which can have an impact in AO and phenotypic variability. 
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A Polineuropatia Amiloidótica Familiar (PAF ATTRV30M) é uma amiloidose 
sistémica autossómica dominante causada por uma mutação pontual no gene da TTR 
(chr18q12.1), que se caracteriza pela dep sição de substância amilóide. Atualmente 
existem mais de 100 mutações descritas no gene da TTR, sendo que a mais frequente 
em Portugal é a substituição V30M. Na população portuguesa, a PAF ATTRV30M 
apresenta uma grande variação na idade de início [19-82 anos] e, em algumas 
famílias, a descendência apresenta uma antecipação na idade de início 
comparativamente aos progenitores. Contudo, a mutação V30M por si só não explica a 
variabilidade da idade de início da doença, observada dentro da mesma família.  
Estudos anteriores em Drosophila, expressando a TTRV30M, demonstraram 
que o gene RAC1 pode estar associado com a variabilidade fenotípica. Assim, este 
seria um bom gene candidato para o estudo da variabilidade da idade de início nos 
doentes PAF ATTRV30M. Para além disso, resultados anteriores numa população 
cipriota evidenciaram uma associação dos genes C1QA e C1QC com a idade de 
início. 
O nosso objetivo foi determinar se estes genes candidatos associados com os 
mecanismos da TTR poderiam atuar como modificadores da idade de início em PAF 
ATTRV30M, analisando pela primeira vez o gene RAC1 e confirmando o envolvimento 
dos genes do complemento C1Q na nossa população.   
Analisámos 267 doentes de 117 famílias e para a pesquisa de polimorfismos 
nos três genes, todos os exões e regiões flanqueantes foram genotipadas por 
sequenciação automática bidireccional. De modo a ter em conta a não-independência 
da idade de início entre membros da mesma família, utilizamos o método generalized 
estimating equations (GEEs) recorrendo ao IBM SPSS software. Posteriormente 
realizou-se uma análise in silico de modo a prever diferenças na regulação da 
expressão génica e para analisar potenciais interações entre os genes.   
Os nossos resultados demonstraram que algumas variantes nos genes RAC1, 
C1QA e C1QC estavam associadas com uma idade de início tardia, tendo um papel 
protetor nos doentes PAF ATTRV30M. Contudo, a maioria das variantes encontradas 
nos genes RAC1 e C1QC estavam associadas com uma idade de início precoce, 
atuando como fatores de risco.  
Na análise in silico encontramos alguns resultados interessantes tendo 
identificado algumas alterações não descritas na ligação de fatores de transcrição e 
ligação de miRNAs nos genes RAC1 e C1QC e no mecanismo de splicing no gene 
C1QA. É de realçar a forte interação encontrada entre os genes C1QA e C1QC 
demonstrando que estes dois genes podem atuar em conjunto como modificadores 
genéticos. 
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Com este estudo, confirmamos o papel dos genes do complemento C1Q nos 
doentes PAF portugueses e revelamos pela primeira vez o papel do gene RAC1 como 
um modificador genético da variabilidade da idade de início. Encontramos resultados 
importantes e até agora não descritos na análise in silico já que alterações nestes 
mecanismos podem levar à desregulação da expressão génica, que pode ter impacto 
na idade de início e na variabilidade fenotípica.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Palavras-Chave: Polineuropatia Amiloidótica Familiar (PAF), V30M, RAC1, 
C1QA, C1QC, idade de início, variabilidade. 
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1.1. Amyloid definition and classification  
 
The Nomenclature Committee of the International Society of Amyloidosis has 
defined amyloid as “extracellular depositions of protein fibrils with characteristic 
appearance in electron microscope, typical X-ray diffraction pattern, and affinity for 
Congo red with concomitant green birefringence” [1].  
Therefore, amyloidosis are a particular group of diseases characterized by 
deposition of insoluble proteins that form amyloid fibrils with 10-12 nm. In addition, the 
amyloid deposits also present secondary components such as serum amyloid P 
component [2].  
The current nomenclature is based on the nature of amyloid fibril protein 
precursor which is designated protein A and then adding the suffix that is an 
abbreviated form of the precursor protein name. We can find many types of 
amyloidosis  according to the precursor protein of amyloid: transthyretin (TTR), 
apolipoprotein A1, gelsolin [2], fibrinogen Aα-chain, lysozyme, cystatin C [3] and 
amyloid β [4]. 
Thus, TTR-related amyloidosis are designated ATTR. In addition, there are also 
some rules for the classification of the variants of fibrillary protein according to the 
different gene mutations. In these cases, the classification was based on the location of 
the amino acid residue preceded by the abbreviation of normal amino acid and 
followed by the abbreviation of mutant amino acid, for example, ATTR V30M [5]. 
The different types of diseases can be identified through the protein name, 
namely systemic AA-amyloidosis and systemic AL-amyloidosis. The first one was 
formerly named secondary or reactive amyloidosis and is a consequence of long-
lasting high expression of the acute-phase amyloid protein serum AA (SAA); the 
second form of amyloidosis referred contains fibrils which are resulting from 
monoclonal immunoglobulin light chains, produced by a plasma cell clone in the bone 
marrow. Rarely, AL-amyloidosis may appear as a localized amyloid type [6].  
 
1.2. History of Familial Amyloid Polyneuropathy (FAP) 
 
In the History of FAP, there can be distinguished essentially four time periods 
along its investigation – an “incubation period” that runs from 1939 to 1952; one second 
period until 1980; a third one, which is defined by the explosion of scientific knowledge 
of the disease; and finally a fourth period that begins with liver transplantation in 1991 
and remains until nowadays [7].  
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In 1939, Corino de Andrade observed in Hospital Santo António, a woman with 
37 years-old who had been living for several years in Póvoa de Varzim. In this case, 
Corino de Andrade found that this women had a peripheral neuropathy, gastrointestinal 
and sphincter perturbations that was known as “foot disease” [8]. In order to clarify this 
study, Corino de Andrade observed twelve more patients and he concluded that they 
were dealing with a new clinical entity [8]. In 1952, Andrade led an extensive anatomo-
clinical study composed by 74 cases and this revealed a high frequency of the disease 
in the population [9]. In 1964, Becker described FAP as an autosomal dominant 
systemic amyloidosis, and revealed for the first time the presence of anticipation in 
some Portuguese families [10].  
 In 1978 there was an evolution in the FAP characterization, when Pedro Costa 
found that the transthyretin (TTR) was the responsible protein for amyloid deposits [11]. 
And a few years later, Tawara and Saraiva described a point mutation in the TTR 
(V30M), which is characterized by the substitution of a valine for methionine at position 
30 in Portuguese, Japanese and Swedish families with FAP [12], [13]. 
 
1.3. Transthyretin amyloidosis 
 
 The TTR amyloidosis can be presented in two forms: hereditary (caused by 
mutations in the TTR gene) and wild-type. The hereditary form of FAP is inherited as 
an autosomal dominant disease [14] which means that only one mutant allele is 
required to develop pathology [15]. 
FAP is characterized by systemic extracellular deposition of TTR amyloid fibrils, 
especially in peripheral nerves, autonomic nervous system tissues, heart, kidneys, 
eyes and gastrointestinal tract [16]. These deposits, in the peripheral nerves, occur in 
the epi-, peri- or endoneurium [4] and they are formed either within the nerve bundles 
or vessels. In most cases it takes the form of rounded masses with more or less regular 
outlines but it may appear in the form of striate or irregular deposits [8]. 
TTR is a soluble plasma protein that binds to thyroxine (T4) and retinol binding 
protein (RBP) in the blood and cerebrospinal fluid [3]. Some studies demonstrated that 
soluble TTR self-assembles into amyloid fibrils as a consequence of point mutations in 
TTR gene originating the amyloidogenic TTR (ATTR) [16]. 
The native form of TTR is a tetramer composed of four equal subunits each of 
which contain 127 residues which form a homotetrameric protein with 56kDa [17]. Each 
monomer contains eight β-strands (A-H) and the global tetramer has two thyroxine-
binding sites and four RBP-binding sites [15]. The molecular structure has determined 
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by X-ray analysis as shown in Figure 1. Two TTR monomers link edge-to-edge to form 
a dimer which is stabilized through antiparallel hydrogen-binding between H-H and F-F 
strands. Subsequently occurs the connection of two dimers through hydrophobic 
interactions between the A-B Loop of one monomer and the H strand of the opposite 
dimer [18].  
TTR has an intermediate affinity for binding to T4 and the ability to carry 
approximately 15% of the total circulating T4, so it is one of the T4 transport proteins in 
plasma and in the cerebrospinal fluid (CSF) [19]. 
The TTR gene is localized on the long arm of chromosome 18 and this gene 
spans ≈ 7 kb containing four exons [15]. It is mostly synthesized by the liver (approx. 
95%) and the remaining 5% is produced by the choroid plexus [20], as TTR does not 
cross the blood-brain barrier [18]. Furthermore, even in small quantities, it can also be 
synthesized in other organs such as in retina, pancreas and intestine [19]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: X-ray structure of transthyretin. In native state, TTR contains eight β-strands (A-H) and a small α-helix 
presented in red. The dimers bind together originating two hydrophobic pockets where T4 binds (T4 channel). PDB 
code: 1DVQ( Adapted from [21]) . 
 
1.3.1. Mutations in TTR 
 
TTR mutations are the most frequent cause of hereditary amyloidosis and more 
than 100 mutations worldwide have been described which report to different 
phenotypes varying from cardiac to neurologic disease [22]. The most common 
pathogenic substitution in FAP is a replacement of valine by methionine at position 30, 
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V30M (V50M, following HGVS) [2]. This change results in a substitution from a 
Guanine to an Adenine in the second exon of the TTR gene [19]. 
Some studies with heterozygous for V30M mutatio  demonstrated that the ratio 
of wild-type TTR and TTR V30M is 2: 1 and 1: 2 in plasma and amyloid fibrils, 
respectively [23]. The pathogenic mutations might decrease the stability of TTR 
tetramers leading to dissociation into monomers [2].  
As previously mentioned, there are mutations that result in more cardiac 
component of the disease such as L111M,  V122I (in the African-American 
population)[3], I68L and T60A while others are more associated with neuropathy such 
as V30M as illustrated in Figure 2 [24]. 
 
Figure 2: Spectrum of correlations between genotype-phenotype in transthyretin-related amyloidosis [25]. 
 
Apart from the already cited mutations, there are other known mutations such 
as the case of TTR L55P and TTR T119M. The first one is a variant with high 
amyloidogenic potential and consequently with a very severe phenotype, with patients 
presenting early-onset (≤ 40 years). On the other hand, the TTR T119M is a non-
pathogenic variant [19], and it has been described in compound heterozygous carriers 
of both TTR V30M and TTR T119M, providing a protective function over the effect of 
TTR V30M since these patients present more stable TTR tetramers leading to a 
delayed disease course [26].  
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1.3.2. Disease pathogenesis 
 
There are many factors involved in the pathogenesis of the disease, including 
fibril precursor protein and the metabolic processing of TTR. 
TTR is a very important plasma protein (20–40 mg/dl) and it has a plasma 
persistence time of only 1–2 days, which must represent a substantial burden to the 
catabolic mechanisms of plasma protein turnover. Furthermore, another factor of TTR 
pathogenesis is the selective involvement of certain systems. The major location of 
amyloid deposition in FAP ATTRV30M is the peripheral nervous system, although the 
gastrointestinal system is also often involved. However, the most frequent cause of 
death is due to abnormalities in the cardiorespiratory system [15].  
The partially formation of unfolded monomers and amyloid aggregates is closely 
related with thermodynamic stability of TTR variants since ATTR presents lower 
thermodynamic stability [18].   
 In the case of V30M mutation, the crystal structure has revealed that this 
substitution results in a small conformational change that is transmitted through the 
protein core to Cys10. Additionally, it is known that this substitution entails the 
separation of the two β-sheets of each monomer, leading to a change in the 
conformation of thyroxine-binding site [18]. 
 Several hypotheses have been developed to explain the mechanisms of TTR 
fibril formation, but two of them were emphasized by Gustavsson A. et al.: the first one 
comprises proteolytic processing of the TTR molecule which produce fibrils with C-
terminal fragments; and the second involves full-length ATTR [19], [27]. 
 As several studies demonstrated that asymptomatic carriers with TTR V30M 
presented nonfibrillar TTR aggregates and the existence of nonfibrillar and fibrillar TTR 
aggregates appears in patients with late-onset (≥50 years), it can be concluded that 
TTR aggregates in the nonfibrillar form were unable to cause toxicity whereas in the 
fibrillary form cause cytotoxicity [19]. 
 Some studies carried out by Miroy and Coworkers had shown that when T4 
binds to TTR, it is able to efficiently inhibit TTR fibrillogenesis in vitro as a result of 
stabilizing the tetramer. Therefore, it was possible to demonstrate that TTR binds to a 
variety of small compounds with molecular structural similarities with T4, which function 
as competitors of T4. These compounds have been the subject of several studies as 
therapeutic alternative in FAP ATTRV30M, albeit with limitations, once many stabilizers 
do not produce any effect when tested ex vivo [19]. 
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The mechanism of TTR aggregation is shown in Figure 3, which mutations in 
TTR lead to dissociation of tetramers in monomers, which posteriorly can aggregate.  
The low-molecular-mass diffusible sp cies binds to the lipid membrane disrupting the 
same, which allows the calcium influx through voltage-gated calcium channels (VGCC) 
from extracellular medium. On the other hand, TTR can bind to a receptor for advanced 
glycation endproducts (RAGE) and disturb the kinase cascade, which induce ER stress 
with consequently release of calcium from intracellular stores. Therefore these 
mechanisms cause cellular damage, death and apoptosis [18]. 
 
Figure 3: Mechanism of TTR aggregation in FAP: 1. Small TTR aggregates stimulate the FAS receptor which in turn 
leads to the activation of the caspase cascade and promote apoptosis. 2. TTR aggregates cause disruption of the 
cellular membrane and consequently, leads to calcium influx from the extracellular medium and calcium efflux from the 
ER. This allows the activation of ER stress and posteriorly the apoptosis, through ER stress – associate caspase-12 
activation. Oxidative stress is also activated by TTR 3. TTR aggregates interact with RAGE stimulating a kinase 
cascade that activates NFkB, which in turn activates the transcription of inflammatory cytokines and oxidative stress 
molecules and consequently increase levels of ROS. 4. Cellular toxicity can also be explained by the existence of still 
unknown receptors for TTR aggregates which are induced by extracellular small non-fibrillar TTR aggregates  (Adapted 
from [18];[19]). 
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1.4. Clinical Manifestations 
 
FAP ATTRV30M has a higher neurological component since it is evident the 
sensorimotor and autonomic polyneuropathy, due to the involvement of non-myelinated 
and small myelinated fibers [28]. Therefore, this disease is commonly characterized by 
the presence of peripheral nerve dysfunction and autonomic dysfunction, which is 
evidenced in the diagram of the Figure 4.  
 
1.4.1. Peripheral Nerve dysfunction 
 
In Portugal, patients showed the first symptoms in their 30’s, and these 
symptoms consists initially in discomfort in the feet, including numbness and 
spontaneous pains [2]. This signs begins in the small nerve fibers altering thermal 
sensitivity, with decreased pinprick sensation. However, light touch and proprioception 
are relatively preserved. Posteriorly, the neurologic deficit progresses with sensory loss 
towards the proximal lower limbs which implies difficulty in walking. At this stage there 
is also a weight loss occurrence and muscle wasting. In addition, Carpal tunnel 
syndrome is an early but nonspecific manifestation of TTR-FAP [24]. Concerning to 
autonomic nervous system it was possible to observe the early loss of unmyelinated 
nervous fibers which plays an important function in the distal component of the 
autonomic nervous system. The progressive denervation of numerous organs can 
contribute to the most frequent clinical manifestations, namely gastrointestinal, 
glandular, vesical, sexual and cardiovascular [29]. 
 
1.4.2. Autonomic dysfunction 
 
The autonomic neuropathy occurs in individuals with early-onset FAP 
ATTRV30M. The circulatory, gastrointestinal and genitourinary systems are affected 
[2].   
Regarding cardiovascular disturbances, there are many causes of its 
occurrence, namely, autonomic disturbances of peripheral blood flow, blood pressure 
and cardiac arrhythmia, because of amyloid accumulation in the heart’s conductive 
system[30]. The first symptom observed is the modification of diastolic function, and 
only in the later stages of the disease, it is possible to observe the cardiac ventricular 
hypertrophy and systolic malfunction [28]. 
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Concerning to gastrointestinal tract, it is regulated by central, intrinsic and 
endocrine-paracrine system. Autonomic nervous system includes alternating periods of 
constipation and diarrhea, nausea, and v miting and neurogenic bladder [24].  It is 
thought that gastrointestinal disturbances may be caused by amyloid infiltration and 
destruction of the celiac ganglion, the vagus nerve and the sympathetic chain ganglia 
and nerves [30]. 
Another system commonly affected is the ocular system, with various symptoms 
such as vitreous opacity, dry eye, glaucoma, pupillary disorders [24], abnormal 
conjunctival vessels (ACV) and keratoconjunctivitis sicca (KCS) [30]. 
Concerning to renal manifestations, in the FAP ATTRV30M patients different 
levels of proteinuria, renal insufficiency, and progression to end-stage renal disease 
(ESRD) have been found [31]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Clinical manifestations in patients with FAP ATTRV30M (Adapted from [32]). 
 
1.5. Epidemiology 
 
V30M is the major variant found in Portugal, but it is described in many other 
countries such as Brazil [33], Sweden [34], Japan [35], France[36], Spain [37], 
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USA[38], China [39], Italy and Greece [40]. The geographical distribution of FAP 
ATTRV30M is shown in Figure 5. 
In northern Sweden, V30M mutation is associated with late-onset cases [15] 
and it has a low penetrance (11% by 50 years)[24]. On the other hand, in northern 
Portugal the same mutation is associated with an earlier onset [15] and has a higher 
penetrance (80% by 50 years) [24]. Since FAP ATTRV30M penetrance is variable from 
country to country, some authors propose that this difference may be explained 
through a combination of genetic and nutrition factors [20]. In addition, penetrance is 
higher when the disease is maternally inherited, which suggest that differences in 
penetrance may be explained by mitochondrial polymorphism [3] or due to an 
imprinting phenomenon [41].  
Epidemiological studies in northern Portugal (Póvoa de Varzim and Vila do 
Conde) shows a prevalence rate of 1/1000 [42] and the incidence is estimated to be 
one in 538 individuals [24]. Therefore, Portugal  has a high prevalence of the disease 
as Sweden and Japan [20].  
 
 
 
Figure 5: Geographic distribution of FAP ATTRV30M (Adapted from [2]). 
 
1.6. Age-at-onset (AO) 
 
In Portuguese patients, the range is from 19 to 82 years and the mean AO of 
the disease is around 33.5 years [43]  and the patients have a rapidly progressive 
sensory-motor and autonomic neuropathy which causes death past 10-20 years [42].  
In Portugal, more and more late-onset cases (≥50 years) have been 
ascertained as well as aged-asymptomatic carriers. So, in previous studies, our group, 
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found that late-onset cases and aged-asymptomatic carriers aggregate in families, and 
that, just like in Sweden, isolated cases with late AO often descend from aged-
asymptomatic carriers [44], [45]. 
In some families the mutation is transmitted through several generations without 
expressing any symptoms. However, this protective effect disappears in the following 
generations leading to a process called genetic anticipation. Anticipation is 
characterized by the existence of a considerably earlier AO (≤ 40 years) in younger 
generations with subsequent increase of the disease severity. In addition, in FAP 
ATTRV30M it has been observed that early and late-onset cases often coexist in the 
same family with progeny showing anticipation (Figure 6) [44].   
Some studies carried out by our group demonstrate that this genetic anticipation 
is significantly higher when the mutation is transmitted by the mother than the father. 
So, the anticipation is more pronounced in mother-son pairs [44]. In spite of the 
mechanism underlying this maternal effect is not yet elucidated, there was some 
hypothesis that may explain this effect such as due an imprinting phenomenon or due 
to existence of a mitochondrial DNA polymorphism that regulate gene expression [41, 
46].  
 
 
 
 
 
 
 
 
 
 
 
However, due to low penetrance and late-onset of TTR mutations in some 
regions, FAP ATTRV30M can exist as sporadic cases [2]. 
Portuguese and Japanese foci of patients with FAP ATTRV30M have been 
described as early AO (33 years), while Swedish patients with FAP ATTRV30M are 
characterized by a later AO (56 years) [24]. 
Anticipation has to be looked in the view of other modifier factors, such as 
genetic modifiers. That is why, candidate genes seem to be a promising strategy to 
identify possible modifiers of AO. 
 Figure 6: Portuguese family showing anticipation throughout three generations. 
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1.7. Clinical Diagnostic 
 
The difficulties of clinical diagnosis of FAP ATTRV30M date sixty years back, 
starting in the first observations of Andrade in 1939 and develops up nowadays [47]. 
Generally, FAP ATTRV30M can be diagnosed through a tissue biopsy 
indicating amyloid deposits by Congo red staining. This tissue sample may be acquired 
from different origins, especially from an affected organ, a nonspecific local with a 70-
80% sensitivity for TTR, abdominal fat pad or salivary gland aspirate [20].  
Another way to diagnose serum variant TTR protein can be detected by mass 
spectrometry, after immunoprecipitation with anti-TTR antibody. Approximately 90% of 
TTR variants exhibit the mass shift predicted by the one amino acid substitution, which 
allows differentiating between wild-type and TTR protein variants in serum. 
Nevertheless, it does not specify the local and type of amino acid substitution in TTR 
gene mutations. That is why, in this cases, DNA sequencing is usually required [24]. 
In some situations, where it is extremely needed a quickly response, namely in 
pre-natal and preimplantation diagnosis, it is necessary to apply new amplification 
methods with real-time detection using hybridization probes [48]. 
In the diagnosis of a hereditary amyloidosis, the knowledge of family history is 
very important, but may not be enough to establish the diagnosis, due to the existence 
of lack of penetrance, advanced AO and variable expression of the disease.  
If a patient has a family history of TTR amyloidosis and the mutation is known, a 
specific DNA testing can be done to discover the concern mutation. On the other hand, 
if a family mutation is not known, it is necessary to carry out full TTR DNA sequencing 
[15]. 
 
1.7.1. Genetic counselling 
 
Genetic counselling is a communication procedure that deals with the risk of 
occurrence of a genetic disorder in the family. In this process is important that family 
realize the medical facts of the disorder, understand how heredity contributes to the 
disorder and their putative risk in specified relatives [49].  
Genetic counselling is an important strategy in FAP ATTRV30M patients with 
early-onset, (as the disease is autosomal dominant) [50] to prevent or delay disease 
progression [51]. Nevertheless, in FAP ATTRV30M with late-onset, genetic counselling 
is more problematic because asymptomatic carriers manifest the disease at a very 
advanced age and it is not possible to predict when the disease will start [50]. 
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For families where the disease appears only in a single family member, is now 
available the presymptomatic testing (PST) for the TTR gene for relatives and the 
follow up of asymptomatic individuals carrying he TTR variant. Thus, this tests can be 
performed in referral centers and in the genetic laboratories [51].  
Currently, there are two techniques that allow a FAP ATTRV30M patient have 
offspring with a very low risk of being carriers of the disease, which are called pre-
implantation genetic diagnosis (PGD) and prenatal diagnosis (PND). 
PND is a diagnostic test carried out on a developing fetus through 
amniocentesis, chorionic villus sampling (CVS), fetal blood sampling, collecting fetal 
sample in maternal circulation or ultrasound. This test is designed to detect a fetus with 
a chromosomal abnormality, congenital malformation or disease, and therefore allows 
the parents the decision to stop the pregnancy in order to prevent the birth of offspring 
with genetic and/or congenital abnormalities.  
On the other hand, the PGD test consists in the analysis of one or two embryo 
cells with three days, allowing the detection of genetic diseases, and only the embryo 
cells without the mutation are implanted in the mother’s uterus [49]. This technique has 
the advantage of not interrupting pregnancy.  
 
1.8. Treatment 
 
The treatment in the FAP ATTRV30M disease can be divided into two principal 
groups: the symptomatic treatment and the etiologic treatment. The first one includes 
the application of pacemaker to treat arrhythmia in later stages of the disease, the 
realization of dialysis in renal perturbations and many others such as the drug therapy; 
and the second one includes many strategies to stop or inhibit the amyloid deposition 
such as liver transplantation [30]. 
As TTR is mostly synthesized by the liver, the only specific treatment for FAP 
ATTRV30M patients is the liver transplantation, where a blockage of mutated protein 
synthesis occurs, leading the formation of amyloid fibrils with pathological effects to 
stop [20]. The first liver transplantation was realized in 1990 in Sweden [52], and since 
then this clinical therapeutic has been performed worldwide [53].  
In spite of this treatment being the most widely accepted, there are reported 
cases of patients in which polyneuropathy have developed after liver transplantation, 
which suggests that once amyloid deposits have accumulated in organs, the process 
can progress to amyloid fibrils from wild-type TTR [20]. Patients with such treatment 
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have a prospect of longer and better quality of life, once liver transplantation eventually 
remove the progressive and fatal nature of the disease. 
Despite the positive results achieved by the introduction of liver transplantation, 
some problems persist, such as limitation of availability of organs, high cost involved, 
the obligation to carry out immunosuppressive therapy for life and the impossibility of 
performing liver transplant patients but not in patients symptomatic, or patients with 
advanced disease [7]. 
There is a new therapeutic option that is used by some countries for FAP 
ATTRV30M treatment – Tafamidis. This drug works through stabilization of TTR 
tetramer and is suitable for treatment of adults with FAP ATTRV30M in the early stage 
[54]. 
Diflunisal is a commercially available nonsteroidal anti-inflammatory agent that 
stabilizes TTR tetramers in vitro, preventing disaggregation, monomer release, and 
amyloid fibril formation by misfolded TTR monomers [55].  
Another type of therapy is the post-transcriptional gene silencing, which is 
capable to inhibit hepatic production of TTR, such as Antisense Oligonucleotides 
(ASOs) and Small Interfering RNA (siRNA). The first one is synthetic sequence of 
nucleotides that binds to the RNA which encodes the targeted protein and 
consequently prevents the translation. An example of this is the ISIS-TTRRX, which is a 
second-generation antisense inhibitor of the molecular target transthyretin [56]. 
On the other hand, the ALN-TTR01 is a lipid nanoparticle-formulation of a small 
interfering RNA targeting wild-type and all mutant forms of TTR. This compound can 
transmit the information to the liver leading to the inhibition of TTR synthesis [56]. 
 
1.9. Genetic modifiers 
 
The wide variability in AO of affected patients is still unexplained. Although 
environmental factors cannot be completely ruled out, the fact is that a large variation 
may still be found within a single geographical area and within the same family. The 
intrafamilial variability raised the hypothesis of a closely linked genetic modifier, since 
the mutation for itself could not explain the variability observed. Therefore, the 
existence of genetic modifiers within or closely linked to the TTR locus can bring new 
insights into AO variability. 
Several studies have been performed regarding genetic and environmental 
factors in order to demystify possible modifier genes. There have already been 
discovered some genetic modulators that may be involved in the variability of the AO in 
   
 15 
 
FCUP 
Unravelling modulators of age-at-onset variability in FAP ATTRV30M 
 
 
Unravelling modulators of age-at-onset variability in FAP ATTRV30M   
FAP ATTRV30M such as  amyloid P component, serum (APCS), complement C1QA 
and C1QC, plasma retinol-binding protein 4 (RBP4) [57] and apolipoprotein E (ApoE) 
[58], but they only explain a small part of AO v riability in FAP ATTRV30M.  
In addition, some studies involving Portuguese families with FAP ATTRV30M 
demonstrated that exist considerable differences between males and females affected 
with the disease, namely that women were found to have later onset when compared to 
men. Accordingly, sex steroid hormones such as androgen receptor (AR) and 
hydroxysteroid (17-β) dehydrogenase 1 (HSD17B1) were studied, since both affect 
TTR expression levels [57]. 
Our group, recently conducted some studies with APCS, RBP4 and AR genes, 
and concluded that they are all involved in the AO variation by using a family-centered 
approach. Regarding sex hormone genes, namely AR gene, our group found for the 
first time significant results showing that, in the male group, the presence of a rare 
allele in any of the variants found is responsible for decreasing the AO. On the other 
hand, in the female group, it was concluded that the heterozygous genotype for almost 
all variants is associated with an earlier AO, with the exception of heterozygous for one 
variant that is associated with late AO. And interestingly, while the SNP in the female 
group causes an increase of AO, in the male group the opposite happens, which 
confirms the existence of extreme differences between genders [57].  
In order to complement our previous studies and confirm that the anticipation is 
mainly transmitted by the mother (70%) than the father (30%) [44], our group 
performed studies to quantify the mitochondrial DNA (mtDNA) copy number in patients 
with FAP ATTRV30M. So they concluded that the highest median of mtDNA copy 
number was found in early-onset patients [unpublished results]. 
In addition, our group go forward to explore candidate genes, so Santos, D. et 
al. analyzed another genes but only six of them were statistically significant (NGAL, 
BGN (only in the female group), MEK1, MEK2, HSP27 and YWHAZ) and concluded 
that they were significantly associated with early- and/or late-onset [unpublished data]. 
Besides the studies already mentioned, our group conducted a study in which 
the main objective was to identify genetic modifiers within the TTR locus, or closed 
linked to it, that might modulate AO, using haplotype study. Thus, a haplotype linked to 
V30M mutation was found and another one that confers some degree of risk to “very 
early” onset patients, which may partially explain the early-onset of progeny, when 
transmitted by the non-carrier parent (trans-effect) [unpublished results].  
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1.9.1. RAC1 
 
The Rho family of GTPases are encoded by 20 genes which have been sub-
classified into various families based on sequence homology: Rac (Rac1-3, RhoG), 
Rho (RhoA-C), Cdc42 (Cdc42, TC10, TCL, Chp/Wrch2, Wrch1), Rnd (Rnd1-2, 
Rnd3/RhoE), RhoD (RhoD, Rif/ RhoF), RhoBTB (RhoBTB1-2) and RhoH [59]. 
Rac plays an important role in communicating cell surface receptors to 
biochemical pathways regulating gene expression. This family comprises 3 isoforms: 
Rac1, Rac2 and Rac3, being Rac1 the most studied isoform [60].  
Ras-related C3 botulinum toxin substrate 1 (RAC1) is located on short arm of 
chromosome 7 (7p22) and comprises 7 coding exons. It is ubiquitously expressed and 
plays a key role at the level of actin cytoskeletal organization and consequently in 
migration of endothelial cells, tubulogenesis, adhesion and endothelial barrier function 
[60]. Rac1 acts a molecular switch that associates with inactive guanosine diphosphate 
(GDP) state and active guanosine triphosphate (GTP) state.  The regulation of GTP-
GDP activation is due to the actions of nucleotide exchange factors (GEFs), GTPase 
activating proteins (GAPs) and Rho guanine nucleotide dissociation inhibitors 
(RhoGDIs) [61].  
The Rho GTPases plays an important role in transcriptional activation, 
membrane trafficking and microtubule dynamics. Therefore, the members of this family 
are involved in many cellular functions as well as cell transformation and invasion, and 
more recently it was found that it is involved also in neuronal development [62]. It has 
been implied that Rac1 and Cdc42 act simultaneously to regulate some functions 
resulting in neurite outgrowth and growth cone development [63].  
The principal mechanism of Rac function in actin cytoskeletal organization is 
illustrated in Figure 7. Rac can activate the p21-activated kinase (PAK) family of 
serine/threonine kinases, which exist in a latent state in the cytoplasm and play an 
important role in regulating actin cytoskeleton. P35 in combination with Cdk5 causes 
hyperphosphorylation of PAK1 and this effect results in its down-regulation. Therefore, 
in order to regulate the PAK activity, Rac can activate PAK and the p35/Cdk5 complex, 
at the same time. Once active, PAK activate LIM domain-containing kinases through 
phosphorylation, which in turn can inactivates cofilin, resulting in actin polymerization. 
On the other hand, PAK can phosphorylate stathmin/Op18 at Ser16, which impedes 
Op18 from binding to microtubules, and subsequently leads to stabilization of 
microtubules. The WAVE family members when interacting with Arp2/3 complex 
promote the last one to nucleate the formation of actin filaments. In the inactive state, 
the WAVE complex is composed by Nap125, PIR121, Abi2 and the heat-shock protein 
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HSPC300. When this complex is added to Rac, occurs its dissociation which promotes 
the release of WAVE and HSPC300 with consequent activation of the Arp2/3 complex 
[62].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Taking into account the mechanism of Rac mentioned above, this one have 
been identified as potential regulator of dendrite and spine development [64], namely it 
induces membrane ruffling and lamellipodium formation [65].  
In the FAP ATTRV30M disease, there are no published studies associated with 
cytoskeleton damage. Nevertheless, some studies carried out by Silva et al. 
(unpublished data) shows that dorsal root ganglia neurons (DRG) (place near where 
occurs TTR accumulation) when treated with TTR oligomers shows cytoskeleton 
modifications. This effect is shown in Figure 8 [66].  
 
 
A B 
Figure 8: Growth cones of the DRG neurons in culture. (A) In a control condition, a DRG 
neuron has the normal actin pattern (red) composed by filopodia and lamellipodia and 
the microtubules (green) are well organized in bundles. (B) DRG neurons treated with 
TTR oligomers present a totally disorganized structure of the growth cone with loss of 
actin structure and the one that is present are organized in spikes of filopodia without 
lamellipodia existing in the structure. Furthermore, the disruption of the microtubules 
structure occurs with consequently formation of a bulb in the tip (Silva, M., unpublished 
results).  
 
Figure 7: Implication of Rac in actin and microtubules dynamics. 
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1.9.2. Complement C1QA and C1QC 
 
C1 comp ement nc mpasses three subcomponents called C1q, C1r and C1s 
which are associated in a calcium-dependent macromolecular complex. This complex 
is activated through conformational changes in the collagen region of the C1q as a 
consequence of its binding to altered acceptor molecules [67]. 
The C1q human molecule with 460kDa  is comprised by 18 polypeptide chains 
of approximately 220 residues each, called A (6A), B (6B) and C (6C) [67] and the 
genes for its chains are located on the short arm of chromosome 1 (1p36.3–p34.1) 
[68]. Each chain aforementioned has a N-terminal region flanked by collagen-like 
region (CLR) and a C-terminal domain (gC1q) [67]. C1QA and C1QC genes are 
composed by three exons, but only two are coding exons. 
This complement is mostly synthesized by myeloid cells namely macrophages, 
monocytes and dendritic cells (DCs) and it is implicated in various cell functions such 
as migration of cells, adhesion, survival and differentiation [67].  
It is believed that C1q could play a dual role in central nervous system (CNS), 
once in some cases C1q seems to be a protector factor by clearance of apoptotic cells 
and blebs and modulating inflammation; on the other hand, in the presence of other 
complement components of the classical pathway, C1q seems to develop neurotoxic 
inflammation [69].  
Accordingly, some brain cells such as astrocytes and microglia express 
complement inhibitors and its function seem to be a protector factor against 
complement-mediated damage. In contrast, neurons are extremely susceptible to 
complement attack, which occurs by complement C1q binding to the membrane of 
neurons and it promotes the activation of classical pathway. However, unlike other 
brain cells, the neurons have a poor capacity to regulate the complement activation 
and they are susceptible to develop tissue damage. As a matter of fact, in 
neurodegenerative diseases, some studies demonstrated that intracellular levels of 
complement are increased, reinforcing what was said above [70].   
 In a previous study, Dardiotis et al. carried out a work with Cypriot FAP 
ATTRV30M carriers, and demonstrated that a polymorphism in the C1QA gene 
(genotype AA of rs172378) was associated with an earlier onset while in the C1QC 
gene, the genotype AA of rs9434 was associated with a later AO. Therefore, C1Q may 
be a modifier gene in FAP ATTRV30M and may explain the genetic anticipation in 
some families [68]. 
In order to further explore AO variation, we decided to study these three 
candidate genes, which seem to be also involved in FAP ATTRV30M pathways.  
   
 19 
 
FCUP 
Unravelling modulators of age-at-onset variability in FAP ATTRV30M 
 
 
Unravelling modulators of age-at-onset variability in FAP ATTRV30M   
 
 
 
 
 
 
 
2. AIMS 
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In this dissertation we intended to determine if a group of candidate genes may 
act as genetic modifiers of AO in individuals with FAP-TTRV30M, since it has been 
observed differences in age-at-onset (AO) between different families and within the 
same family, in the Portuguese population 
Therefore, the principal aims of this dissertation are: 
 Investigate candidate genes (RAC1, C1QA and C1QC) as a potential genetic 
modifier of AO in the FAP ATTRV30M; 
 In silico analysis of the variations found in the genes under study and its 
implication in gene expression and variability of AO in the FAP ATTRV30M.  
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3. METHODS 
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3.1. Sample Study 
 
Unidade Corino de Andrade (UCA-CHP, Porto) has the largest FAP ATTRV30M 
registry worldwide, that was collected over 75 years and clinically well characterized. 
The present study is composed by 267 affected individuals with FAP ATTRV30M from 
117 families currently under follow-up at UCA-CHP, which came from different 
geographical areas of country. The AO of each individual were established by the 
same group of neurologists, after the manifestation of the first symptoms.  
The DNA samples of the patients were collected and stored at Centro de 
Genética Preditiva e Preventiva (CGPP, Porto, Portugal) biobank, authorized by CNPD 
(National Commission for Data Protection). It is important to note that all samples were 
obtained with informed consent of the individuals and all legal and ethical procedures 
were taken. 
 
3.2. Genotyping of RAC1, C1QA and C1QC 
 
3.2.1. DNA extraction 
 
Genomic DNA was collected from peripheral blood leucocytes, using the 
QIAamp® DNA Blood Mini Kit (QIAGEN™) or from saliva using ORAGENE DNA Self 
Collection Kits (DNA Genotek, Ottowa, Canada) according to manufacturer’s 
instructions. 
 
3.2.2. Determination of DNA concentration using Nanodrop 
 
In order to evaluate concentration and purity of genomic DNA, we extract 2 μL 
of each sample and analyze using the NanoDrop Spectrophotometer ND-1000 
(Thermo Scientific). Purity is a parameter given by the A260/A280 ratio and 
concentration is expressed in μg/μL. 
 
3.2.3. Primer design and amplification of DNA using conventional 
PCR 
  
Primers were designed using Primer3Plus software and afterwards the 
existence of dimer and hairpin formation, as well as polymorphisms was excluded 
using the AutoDimer and SNPcheck softwares, respectively. 
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We consider all RAC1 amplicons with a flanking region of 60 bp and C1QA and 
C1QC amplicons with a flanking region of 50 bp. Additionally, we consider more 100 bp 
for the 3’UTR. The primers’ sequenc s that we e us d are presented in able 13 in 
Appendix. 
A polymerase chain reaction (PCR) was performed to amplify genomic DNA of 
the patients for the three genes under study. Therefore we used a PCR Master Mix 
composed by H2O, HotStarTaq DNA polymerase® (Qiagen™), and primers (forward 
and reverse) for each exon of every gene. The protocol that was used is presented in 
Table 15 in Appendix. However, this protocol was not used for Exon 1 of RAC1, since 
this sequence is very rich in guanine (G) and cytosine (C). So it was necessary to 
replace the H2O by DMSO, and the protocol is shown in Table 14 in Appendix. 
DMSO is the most commonly used enhancing agent and this facilitate strand 
separation[71]. This is particularly useful in sequences with high GC content because 
the increased hydrogen bond strength increases the difficulty of denaturing and 
promote the capacity of the intermolecular secondary structures to form more readily, 
which can compete with primer annealing [72]. 
Additionally, the conditions used in protocols in this step are presented in Table 
16 and Table 17 (for RAC1 gene), Table 18 (for C1QA gene) and Table 19 (for C1QC 
gene) in Appendix. 
Posteriorly, we use the Qiaxcel® BioCalculator equipment in order to verify 
amplification of PCR products and to exclude possible contaminations.  
 
3.2.4. Purification 
 
Before proceeding to the next step is necessary to perform the purification of 
PCR products in order to remove unincorporated primers and dNTPs. For this purpose, 
we used ExoProStar™, which is able to remove these contaminants and the protocol 
as well as the conditions are presented in Table 20 and Table 21 in Appendix.  
 
3.2.5. Sequencing 
 
After the purification step, we proceed with the sequencing stage. The reaction 
was performed using Big Dye Terminator Cycle Sequencing v1.1, and the protocol as 
well as conditions underlying this reaction are presented in Table 22 and Table 23, 
respectively, in Appendix. After, sequencing capillary electrophoresis was performed in 
ABI Prism 313xl Sequencer analyzer (Applied Biosystems TM), and further analyses of 
sequences were carried out using Seqscape v2.6 software (Applied Biosystems TM). 
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In order to confirm if the variants found are already described, we used the 
Alamut Mutation Interpretation Software (Interactive Biosoftware, Rouen France). 
In cases of polymorphisms with uncertain genotypes or that are undescribed, these 
were confirmed and evaluated again by sequencing. 
 
3.3. Statistical analysis 
 
Since we included in the analysis several members of the same family, each 
patient was “nested” in his/her family. For this purpose analyses were conducted taking 
into account the non-independency of AO, using generalized estimating equations 
(GEEs).  
In this model, we associate the different variants with AO (which is the 
dependent variable), using the most common genotype as the reference and adjusting 
for gender. 
The unstandardized coefficient (B) corresponds to the mean AO variation 
observed in the individuals carrying a specific genotype when compared with the 
reference category. To correct for multiple testing, we applied a Bonferroni correction 
(α was set at 0.02 in the GEE analysis). All these statistical analyses were performed 
using IBM SPSS Statistics software (v.23).  
 
3.4. In silico analyses  
 
We used bioinformatics tools to perform in silico analyses such as Polyphen-2 
to predict the impact of sequence variants on gene function and SNP Function 
Prediction (FuncPred) to predict putative SNP functional effects. In order to deepen the 
results obtained in FuncPred, we used other bioinformatics tools according to what we 
wanted to explore in more detail. Thus, to predict how likely a splicing change would 
occur as a result of the presence of the SNP, we used two prediction programs: ESE 
(Exonic Splicing Enhancer) Finder v3.0 and Human Splicing Finder (HSF) v3.0. 
On the other hand to predict whether an allele change of a 3’UTR SNPs lead to 
a disruption or creation of novel miRNA binding sites, we used mirDIP dataset which 
includes twelve different datasets [73]. 
In addition, to predict miRNA targets in the 3’ UTR and the most conserved 
miRNA in the WT sequence we used miRWalk.As the mirDIP software, this software 
integrates other eleven softwares, DIANA-microT, miRanda, mirbridge, miRDB, 
miRMap, miRNAMap, Pictar2, PITA, RNA 22, RNAhybrid and Targetscan. 
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To further explore which non-coding variants create new Transcription Factor 
Binding Sites that can regulate gene expression, we used rSNP-MAPPER software, 
taking into account TRANSFAC, MAPPER and JASPAR models. 
In order to search possible gene-gene interactions, we used Multifactor 
Dimensionality Reduction (MDR) software (v2.0), which is a nonparametric and genetic 
model approach that allows to compare early and late onset patients and to identify 
which combinations of SNPs were involved in the disease vulnerability. Posteriorly, the 
significant results were corrected for multiple testing, based on 1000-fold permutation 
test, using MDR Permutation Testing Module (v1.0). 
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4. RESULTS 
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4.1. Descriptive analysis  
 
Our analyses included 267 individuals with FAP ATTRV30M from 117 families, 
and the mean AO of our sample is 39.66 years. In the following table we can find the 
descriptive analysis of AO distribution, between males and females. 
 
 Table 1: AO distribution between males and females, in our sample. 
 
According to the results presented in Table 1 the mean AO in the male group 
was 38.11 years, whereas in the female group the mean AO was 41.21 years. So, as 
described in the literature, the mean AO in males is lower than in females [44]. 
It is important to note that it was necessary to exclude some DNA samples due 
to problems in the integrity and concentration of DNA. 
 
4.2. Genotypic analysis 
 
4.2.1. Variants presented in RAC1 gene 
 
Through genotyping of coding and flanking regions of the RAC1 gene, it was 
possible to find 16 variants: 14 in the intronic region and 2 in exonic region, which were 
already described (Table 2). From these, we found 8 variants significantly associated 
with AO (Table 3).  
 
 
 
 
 
 
 
 AO (years) 
Gender N  Range Minimum Maximum Mean Standard 
Deviation 
Variance 
Males 134 51 21 72 38.11 13.81 190.67 
Females 133 50 21 71 41.21 12.26 150.32 
Total 267 51 21 72 39.66 13.13 173.34 
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Table 2: Variants found in RAC1 gene 
dbSNP ID Location Region 
Effect on 
protein 
(Polyphen-2) 
Frequency of 
common allele 
(HapMap: EUR-
CEU) 
Frequency of 
mutant allele 
(HapMap: EUR-
CEU) 
rs34500835 c.36-52G>A Intron 1 N.A. G (1.000) A (0.000) 
rs369301942 c.108-47A>G Intron 2 N.A. A (1.000) G (0.000) 
rs702483 c.107+27C>T Intron 2 N.A. C (0.540) T (0.460) 
rs3729789 c.107+39C>T Intron 2 N.A. C (0.995) T (0.005) 
rs3729790 c.107+40G>A Intron 2 N.A. G (0.803) A (0.197) 
rs836478 c.225+18C>T Intron 3 N.A. C (0.540) T (0.460) 
rs762492724 c.283-40G>C Intron 4 N.A. G (1.000) C (0.000) 
rs200639704 c.282+14T>G Intron 4 N.A. T (1.000) G (0.000) 
rs118039194 c.282+39C>T Intron 4 N.A. C (0.995) T (0.005) 
rs749782387 c.345+24A>G Intron 5 N.A. A (1.000) G (0.000) 
rs144607000 c.345+60C>G Intron 5 N.A. C (0.995) G (0.005) 
rs200222012 c.506-35G>A Intron 6 N.A. G (1.000) A (0.000) 
rs3729796 c.505+12T>C Intron 6 N.A. T (0.995) C (0.005) 
rs2303364 c.505+30T>C Intron 6 N.A. T (0.955) C (0.045) 
rs61753123 
c.552C>G, 
p.Leu184Leu 
Exon 7 
Synonymous 
(Benign) 
C (0.995) G (0.005) 
rs144425992 
c.603G>A, 
p.Val201Val 
Exon 7 
Synonymous 
(Benign) 
G (1.000) A (0.000) 
N.A.: Non Applicable 
CEU - Caucasian population  
 
Using Polyphen-2, we found that exonic variants had a benign impact in RAC1 
function, since we are dealing with synonymous substitutions.  
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Table 3: Statistically significant variants in RAC1 gene 
 
From the eight statistically significant polymorphisms (sequencing results can 
be found in Annex 2 of the Appendix), six of them (rs3729789, rs200639704, 
rs118039194, rs762492724, rs200222012 and rs144425992) were associated with an 
earlier onset, leading to a decrease in the mean AO between 4 and 14 years. The other 
two variants (rs749782387 and rs144607000) were associated with a later onset 
corresponding to an increase of 5 years and 29 years in mean AO, respectively.  
After Bonferroni correction, it was found that rs118039194 was no longer 
statistically significant. 
 
4.2.2. Variants found in C1QA gene 
 
After genotyping of coding and flanking regions of the C1QA gene, we found six 
variants: one in intronic region and five in exonic region, which were already described 
(Table 4); two of those variants were statistically significant (Table 5).  
 
 
 
Variant B Genotype 
95% Wald Confidence 
Interval 
P-value 
 
Intercept 36.64 
 
[32.79; 40,50] <0.001 
1. rs3729789 
- 
-9.82 
CC (Reference) 
CT 
- 
[-15.46; -4.19] 
- 
0.001 
2. rs762492724 
- 
-10.45 
GG (Reference) 
GC 
- 
[-14.21; -6.69] 
- 
<0.001 
3. rs200639704 
- 
-7.05 
TT (Reference) 
TG 
- 
[-10.26; -3.83] 
- 
<0.001 
4. rs118039194 
- 
-4.40 
CC (Reference) 
CT 
- 
[-8.58; -0.23] 
- 
0.039 
5. rs749782387 
- 
5.36 
AA (Reference) 
AG 
- 
[1.50; 9.21] 
- 
0.006 
6. rs144607000 
- 
28.55 
CC (Reference) 
CG 
- 
[24.79; 32.32] 
- 
<0.001 
7. rs200222012 
- 
-7.45 
GG (Reference) 
GA 
- 
[-11.21;-3.69] 
- 
<0.001 
8. rs144425992 
- 
-14.05 
GG (Reference) 
GA 
- 
[-17.26; -10.83] 
- 
<0.001 
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Table 4: Variants found in C1QA gene. 
dbSNP ID Location  Region 
Effect on 
protein 
(Polyphen-2) 
Frequency of 
common allele 
(HapMap: EUR-
CEU) 
Frequency of 
mutant allele 
(HapMap: EUR- 
CEU) 
rs201693493 
c.125 G>A 
p.Arg42Gln 
Exon 2 
Missense 
(Benign) 
G (1.000) A (0.000) 
rs369926227 c.163+35C>A Intron 2 N.A. C (1.000) A (0.000) 
rs172378 
c.276 A>G 
p.Gly92Gly 
Exon 3 
Synonymous 
(Benign) 
A (0.601) G (0.399) 
rs180679721 
c.295 A>C 
p.Ile99Leu 
Exon 3 
Missense 
(Benign) 
A (1.000) C (0.000) 
rs149050968 
c.525 C>T 
p.Ile175Ile 
Exon 3 
Synonymous 
(Benign) 
C (1.000) T (0.000) 
rs765715625 
c.609G>C 
p.Gly203Gly 
Exon 3 
Synonymous 
(Benign) 
G (1.000) C (0.000) 
N.A. Non Applicable 
 
Polyphen-2 software shows that all variants found had a benign function in 
C1QA gene, wherein two of them are missense substitutions and the other three are 
synonymous substitutions. 
 
Table 5: Statistically significant variants in C1QA gene. 
 
The two statistically significant polymorphisms (rs201693493 and rs149050968) 
were associated with a late-onset corresponding to an increase of 16 years and 10 
years in mean AO, respectively. 
 
 
 
 
Variant B Genotype 
95% Wald Confidence 
Interval 
P-value 
 
Intercept 39.11 
 
[35.69; 42.53] <0.001 
1. rs201693493 
- 
15.85 
GG (Reference) 
GA 
- 
[13.02; 18.67] 
- 
<0.001 
2. rs149050968 
- 
10.13 
CC (Reference) 
CT 
- 
[6.97; 13.28] 
- 
<0.001 
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4.2.3. Variants identified in C1QC gene 
 
When we analyzed C1QC gene, it was possible t  find 7 variants, which were 
already described (Table 6). The exonic variant is a synonymous substitution, so it has 
a benign effect on protein. The 4 statistically significant polymorphisms are presented 
in Table 7. 
 
Table 6: Variants found in C1QC gene 
dbSNP ID Location  Region 
Effect on 
protein 
(Polyphen-2) 
Frequency of 
common allele 
(HapMap: EUR-
CEU) 
Frequency of 
mutant allele 
(HapMap: EUR-
CEU) 
rs2935537 c.-3G<A 5’UTR N.A. G (1.000) A (0.000) 
rs74909167 c.-13-72G>A Intron 1 N.A. G (0.995) A (0.005) 
rs15940 
c.126C>T 
p.Pro126Pro 
Exon 2 
Synonymous 
(Benign) 
C (0.732) T (0.268) 
rs36049190 c.182-21C>G Intron 2 N.A. C (0.914) G (0.086) 
rs200952686 c.*5G>A 3’UTR N.A. G (1.000) A (0.000) 
rs201241346 c.*14G>A 3’UTR N.A. G (1.000) A (0.000) 
rs9434 c.*21C>A 3’ UTR N.A. C (0.601) A (0.399) 
 
 
Table 7: Statistically significant variants in C1QC gene. 
 
Three of the statistically significant polymorphisms (rs2935537, rs15940 and 
rs201241346) were associated with an early-onset corresponding to a decrease 
 
Variant B Genotype 
95% Wald 
Confidence Interval 
P-value 
 
Intercept 38.60 
 
[34.69; 42.50] <0.001 
1. rs2935537 
- 
-6.85 
GG (Reference) 
GA 
- 
[-11.33; -2.36] 
- 
0.003 
2. rs15940 
- 
-5.25 
CC (Reference) 
CT/TT 
- 
[-10.19; -0.31] 
- 
0.037 
3. rs200952686 
- 
31.91 
GG (Reference) 
GA 
- 
[28.74; 35.07] 
- 
<0.001 
4. rs201241346 
- 
-10.86 
GG (Reference) 
GA 
- 
[-13.95; -7.77] 
- 
<0.001 
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between 5 and 11 years in the mean AO, whereas the rs200952686 was associated 
with a late-onset with an increase of ≈32 years in mean AO. However, after the 
Bonferroni correction, rs15940 was no longer statistically significant. 
 
4.3. In silico analyses  
 
To unravel possible regulatory effects of the variants found, we used SNP 
Functional Prediction (FuncPred) software, as a first approach. This software allows us 
to explore possible changes at the level of transcription factors binding sites (TFBSs), 
miRNAs, and splicing sites. 
Our analyses included the variants found but also polymorphisms in linkage 
disequilibrium (LD) with the ones we identified. The study of LDsnps in the human 
genome allows the identification and characterization of additional genetic variants in 
order to cover the entire genetic information of the genes studied [74]. 
 
4.3.1. TFBSs 
 
The variants found to change TFBS are presented in Table 8. 
 
Table 8:  Variants predicted to alter TFBS. 
Genes SNPs Model TF Score 
RAC1 
rs3729790 M00453 IRF-7 4.5 
rs702483 M00011 Evi-1 4.0 
C1QC 
rs2935537 M00531 NERF1a 3.8 
rs294180 (LDsnp rs9434) M00732 CAT8 3.9 
 
The rSNP-MAPPER software highlighted that rs3729790 may alter the binding 
of IRF-7 and rs702483 affects the consensus motifs of Evi-1, both in RAC1 gene.  
In the C1QC gene, we found that rs2935537 may change the binding of 
NERF1a and rs294180 (LDsnp rs9434) leads to alteration in CAT8. 
 
4.3.2. miRNA target predictions 
 
In Table 9, we present the miRNA target predictions for WT and minor allele of 
rs9374 (LDsnp rs3729790) and rs6951997 (LDsnp rs3729796) in the RAC1 gene. 
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Table 9: miRNA target predictions associated to SNPs using miRDIP software. 
Gene SNPs LDsnps WT allele Minor allele 
RAC1 
rs9374 rs3729790 
hsa-miR-4427 
hsa-miR-3653-3p 
hsa-miR-5187-3p 
hsa-miR-5585-3p 
hsa-miR-4680-3p 
hsa-miR-4539 
rs6951997 rs3729796 
hsa-miR-4733-3p 
hsa-miR-6776-3p 
hsa-miR-1226-3p 
hsa-miR-4773 
 
 
We found in RAC1 gene two SNPs in LD with rs3729790 and rs3729796 that 
create a new possibly target site for hsa-miR-4539 and hsa-miR-4773, respectively. 
In C1QC gene, FuncPred software predicted changes at the level of miRNA. 
However, when we used other miRNA prediction software, particularly mirDIP software, 
we did not find any significant results. 
 
4.3.3. Splicing activity  
 
Using FuncPred software was possible to find that rs172378 of C1QA gene 
causes alterations in Exonic Splicing Enhancer (ESE) or Exonic Splicing Silencer 
(ESS) motifs.  To further explore these results, we used Human Splicing Finder (HSF) 
software to detect specific alterations in splice sites (Table 10) and ESEfinder software 
to detect modifications on ESE motifs (Table 11).  
 
Table 10: Splice sites predictions by HSF software 
CV – Consensus Value 
 
We found two SNPs in C1QA gene with possibly effect in the splicing 
mechanism.  rs172378 reduce the CV of an acceptor site (CV= 46.68) and a branch 
point comparing to WT (CV= 44.26). For rs201693493 we found a mild reduction in an 
acceptor site but more interestingly this SNP creates a significant increase in another 
acceptor site (CV>80) comparing to WT.  
Gene SNPs Splice Sites WT CV Mutant CV Variation  Effect 
C1QA 
rs172378 
acceptor site 75.63 46.68 -38.28 Site Broken 
branch point 73.89 44.26 ------ Site Broken 
rs201693493 
acceptor site 54.12 83.06 53.47 New site 
acceptor site 76.51 76.32 -0.25 ------ 
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Table 11: ESE alterations predictions by ESEfinder software. 
SR proteins –  Ser/Arg-rich proteins 
 
Despite both SNPS, rs172378 and rs149050968 in C1QA, increasing the motif 
score compared to WT they don’t affect the SR protein sites. 
For C1QC gene, when we analyzed variants in FuncPred software, it was 
possible to find splicing predictions. Nevertheless, when we analyzed the variants in 
prediction software splicing factors, we did not find significant results. 
 
4.4. Summary table of result 
 
 
 
Gene SNPs SR Protein 
Motif 
Threshold 
WT 
Score 
Mutant 
Score 
C1QA 
rs172378 
SC35 site 2.38 3.78 5.54 
SF2/ASF site 1.96 2.29 3.22 
SF2/ASF (IgM-BRCA1) site 1.87 1.93 2.17 
rs149050968 SRp40 site 2.67 2.70 3.06 
Table 12: Summary of in silico regulatory analyses caused by variants found. 
Genes SNPs LDsnps TFBSs miRNA target site Splicing activity 
    WT Mutant ESE HSF 
RAC1 
rs3729790 ---- IRF-7 ---- ---- ---- ---- 
rs9374 rs3729790 ---- 
hsa-miR-4427 
hsa-miR-3653-3p 
hsa-miR-5187-3p 
hsa-miR-5585-3p 
hsa-miR-4680-3p 
hsa-miR-4539 ---- ---- 
rs702483 ---- Evi-1 ---- ---- ---- ----- 
rs6951997 rs3729796 ---- 
hsa-miR-4733-3p 
hsa-miR-6776-3p 
hsa-miR-1226-3p 
hsa-miR-4773 
 
---- ----- 
C1QA 
rs172378 ---- ---- ---- ---- 
SC35 
SF2/ASF 
SF2/ASF 
(IgM-
BRCA1) 
Site 
Broken 
rs201693493 ---- ---- ---- ---- ---- New site 
rs149050968 ---- ---- ---- ---- SRp40 ---- 
C1QC 
rs2935537 ---- NERF1a ---- ---- ---- ---- 
rs294180 rs9434 CAT8 ---- ---- ---- ---- 
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4.5. Interactions between genes 
 
We assessed a putative C1QA-C1QC gene interaction using MDR and it was 
possible to find two significant interactions, in the group of patients with late-onset 
when comparing with early-onset patients. The first interaction found was between 
rs172378 of the C1QA gene and rs15940 of the C1QC gene, with testing balance 
accuracy (TBA) of 0.54 and a cross-validation consistency (CVC) of 8/10. After we 
performed a permutation test, we obtained a significant TBA of 0.67 and a CVC of 
10/10 (p= 0.002). The second interaction found was between rs172378 of the C1QA 
gene and rs15940 plus rs74909167 of the C1QC gene with a TBA of 0.61 and a CVC 
of 10/10. After permutation test, the values mentioned above were the same and were 
statistically significant (p=0.04). 
When we assessed the RAC1-C1QA-C1QC gene interactions, we did not found 
any significant results. 
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5. DISCUSSION 
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Age-at-onset (AO) variability is a hallmark of FAP ATTRV30M. Unlike other 
neurodegenerative diseases, characterized by dynamic expansions, as Huntington’s 
disease (HD), the point mutation found in TTR d es not dete mine AO variation. To 
explore other possible genetic factors that modulate AO in FAP ATTRV30M, we 
performed a family-centered approach and focused on candidate genes that can affect 
functional pathways in the course of disease.  
 
5.1. Candidate genes associated with AO variability 
 
5.1.1. RAC1 gene 
 
We found five significant variants in this gene associated with an early-onset. 
Therefore we hypothesize that these variants could be a risk factor for AO in FAP 
ATTRV30M patients. On the other hand, two other significant variants were associated 
with a late AO, which suggests that these variants may have a protective effect. 
However, it is important to note that in all the variants detected, with the 
exception of rs3729789, the heterozygous genotype only appears once in our sample, 
which is in accordance with the observed genotypic frequencies of the European 
population in the HapMap and 1000 genomes databases, and therefore we think that 
this result is worth mentioning. In addition, as most variants found are rare we analyzed 
the heterozygous and the rare homozygous together in order to achieve a higher 
statistical power. 
Rac has been implicated in axon growth and guidance [75], whereby has a 
protective function against apoptosis-mediated neurodegeneration [61]. Taking this into 
account, a study carried out by Silva et al using D. melanogaster expressing TTRV30M 
demonstrated that the presence of Rac1 plays a protective factor against rough eye 
and severe phenotype. On the other hand, flies expressing Rac1 dominant-negative 
(DN)  lead to the appearance of rough eye phenotype and the expression of 
constitutively active form of Rac1 is fatal [66]. This finding emphasizes the importance 
of Rac1 regulation during development and may explain the absence of homozygous in 
our sample.  
In addition, dysregulation of Rho GTPases pathways (in which RAC1 is 
involved) appears to underlie the etiology of several neurodegenerative diseases such 
as Alzheimer’s disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington’s 
disease (HD) and Parkinson’s disease (PD). Therefore, using these Rho GTPases and 
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more specifically Rac1 as targets, it can be a useful therapeutic strategy for the 
treatment of these disorders [76]. 
Our results are in accordance with these findings, since rs749782387 and 
rs144607000 may modulate the protective role of RAC1, leading to a delay in disease 
onset. On the contrary, the other variants found seem to interfere with the active state 
of Rac1, potentially promoting GDP-binding, leading to its inactive state, and 
consequently to an early disease onset.  
Interestingly, rs144425992 is a coding variant leading to a decrease in AO, in 
approximately 14 years. In fact it is interesting to note that the carrier of this variant has 
a very early-onset (23 years). Therefore, this variant can be a genetic risk factor for AO 
in FAP ATTRV30M patients. 
To further explore the role of RAC1 gene in FAP ATTRV30M, we performed in 
silico analysis.   
We found that rs3729790 may lead to an alteration of the binding of the IRF-7 
factor and can also interfere with the putative binding to target site of the hsa-miR-
4539, when the minor allele of rs9374 (LDsnp rs3729790) is present. 
Some studies demonstrated that IRF7 may interact and be acetylated by 
histone acetyltransferases (HATs) p300 and CBP, leading to the increase of 
transcriptional levels [77]. In this study, we found that rs3729790 probably leads to an 
early-onset, despite there is no statistical evidence to prove this fact (data not shown). 
Taking into account this, we can assume that this SNP may lead to an alteration 
of the binding of the IRF-7 factor decreasing the transcription of RAC1 gene. This fact 
is reinforced by enabling the binding of a new miRNA, hsa-miRNA-4539 which does 
not bind in the WT variant. These two mechanisms together possibly leads to a 
downregulation of RAC1 expression contributing for an early AO. 
We also found other five miRNAs with the putative binding of target sites for the 
WT allele of rs9374 (LDsnp rs3729790). However, the minor allele of this variant does 
not interfere with these miRNAs, leading us to conclude that these five miRNAs may 
not be related with AO variability of FAP ATTRV30M. 
We also found that rs702483 may change the consensus motifs of the Evi-1 
factor. The Evi-1 may activate transcription or more generally may act as a 
transcriptional repressor [78] dependent on DNA binding through either the first or the 
second zinc-finger domain [79]. It has been thought that many transcriptional 
repressors interact with histone deacetylases (HDACs) and contribute to tight 
nucleosomal packing of DNA [78]. Since this transcription factor may contribute to the 
decrease of transcriptional levels it can lead to a downregulation of RAC1 expression. 
However, we found that this variant is associated with an increase in the mean AO in 
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human FAP ATTRV30M patients (data not shown) which can be due to an alteration in 
Evi-1 binding leading Evi-1 activate transcription which promote RAC1 expression and 
consequently acting as protective modifier. 
Additionally, we also found that rs6951997 (LDsnp rs3729796) is related with 
miRNA binding alterations as hsa-miR-4773 leads to an alteration of target binding 
sites. Since rs3729796 probably tend to increase mean AO, we can hypothesize that 
this miRNA leads to an upregulation of RAC1 expression, and therefore plays a 
protective role for FAP ATTRV30M carriers. 
 
5.1.2. C1QA and C1QC genes 
 
In a previous study carried out in Cypriot FAP ATTRV30M patients, Dardiotis et 
al., 2009 found that the genotype AA of rs172378 in the C1QA gene was associated 
with an early AO. Also, in the same study, it was described that rs9434 in the C1QC 
gene modulates AO, leading to an increase in AO [68]. Therefore, these results show 
that these genes may be considered genetic modifiers in FAP ATTRV30M Cypriot 
population. Importantly, this study did not take into account family structure [80]. We 
found in our study two statistically significant variants in C1QA gene associated with 
late AO and we can hypothesize that these variants could be a protective factor for 
FAP ATTRV30M patients.  
Regarding the variants found in C1QC gene, three are statistically significant 
associated with an early AO and one variant associated with a late AO. 
Similarly to what was found for RAC1 gene, for C1QA and C1QC genes, in 
some variants the heterozygous genotype only appears once in our sample, which is in 
accordance with the genotypic frequencies described in HapMap and 1000 genomes 
databases. However, as we found significant results for these genotypes, we 
considered that these results should be reported in order to assess their implications in 
AO variation and to unravel more data on SNPs frequency in FAP ATTRV30M 
Portuguese population. 
In our sample we also studied the variants found in the Cypriot population, but 
the results obtained were not statistically significant, leading us to conclude that these 
polymorphisms are not related with AO variability in our population. This evidence 
suggests that different approaches can lead to different results. Furthermore, it is 
important the different genetic background between populations that can result in 
different disease mechanisms. Additionally, this conclusion had already been raised in 
a previous study of our group, when they analyzed the role of APCS gene in AO 
variability, and concluded that our results were different from those carried out by 
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Dardiotis et al., 2009. Furthermore, their samples’ size was quite small when compared 
to ours, showing that increasing sample size will increase statistical power. 
C1Q complement genes have demonstrated to play an important role in other 
neurodegenerative diseases as Alzheimer’s disease (AD) and Parkinson’s disease 
(PD) [81]. The complement system can have a double role, beneficial or damaging, 
depending on the associated pathophysiological mechanisms as in some cases it can 
lead to tissue damage [70]. On contrary, in AD it was demonstrated under some 
circumstances, that C1Q plays a protective role and downregulates the inflammation 
process, in the early stages of neuronal injury as well as amyloid induced neurotoxicity 
[82].  
In our sample occurs a mechanism similar to that already described for 
Alzheimer's patients as variants found in C1QA gene seem to be involved in an 
increase in mean AO as well as the rs200952686 in the C1QC gene. 
In contrast, the remaining variants that were found in C1QC gene may play a 
risk factor for FAP ATTRV30M patients, and possibly leads to tissue damage.  
Regarding in silico analyses for C1QA gene, we found that rs172378 and 
rs20163493 presents significant splicing alterations.  
In the region of rs172378, a weaker splice site existent in WT variant can 
possibly result in an inactive conformation when the mutant variant is introduced. In the 
analysis of rs201693493 we found a different effect, with strong active splice site in the 
mutant sequence, leading to the creation of a new splice site. In most cases, the 
variants which implies unnatural splice sites or intron retention leads to the premature 
termination codons (PTCs) into the mRNA, resulting in degradation by nonsense-
mediated decay (NMD) and loss of function of the minor allele [83]. Thus, this may 
explain the association of this variant with a late-onset of the disease.  
Taking into account the scores obtained in ESEfinder and the results presented 
in Table 11, we concluded that there is no disruption or ESE creation due to the 
variants found. 
For C1QC gene, we found that rs2935537 may alter the binding of NERF-1a 
factor. NERF (new-ETS-related factor) belong to ETS-domain family which plays an 
important role in the transcriptional control and may act as either transcriptional 
activators or repressors. So, this transcription factor seems to be involved in the 
regulation of cellular proliferation, differentiation both in embryonic and adult 
development, and in tissue specificity [84]. 
Some studies demonstrated that NERF-1a and NERF-1b lack significant 
transactivation capabilities, so they act as negative regulators. In addition, one study 
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revealed that NERF1 act as a topoisomerase II, and both repressed basal transcription 
[85]. 
Since NERF1a contribute to the decre se f transcriptional levels, promoting a 
downregulation of C1QC gene expression, we can postulate that rs2935537 plays a 
risk factor for the FAP ATTRV30M patients. In this case, it seems that complement 
levels confer a protective effect, which is lost in the presence of the polymorphism. 
Thus, this variant leads to a decrease in complement levels, which according to some 
authors may be associated with an increase of the autoimmune response. This 
argument corroborates the decrease in the mean AO caused by this SNP.  
We also found that rs294180 (LDsnp rs9434) may result in the alteration of the 
CAT8 factor binding. 
Despite rs9434 is associated with a late AO in our sample (data not shown), 
these results were not statistically significant. However, the delayed onset of symptoms 
in these patients can partly be explained by the role of CAT8 factor in derepression of 
gluconeogenesis enzymes [86],  leading to better glucose delivery in the brain [87], and 
it may play a protective role in FAP ATTRV30M carriers. 
 
5.2. The importance of in silico analyses: functional 
implications 
 
Deciphering the molecular basis of genetic diseases is supported by the 
availability of high throughput strategies for the identification of pathways associated 
with disease mechanism [88]. To explore functional implications of SNPs found, we 
performed in silico analyses including alterations in Transcription Factors Binding 
(TFBSs), miRNA target sites and splicing activity. In silico softwares have in the past 
few years emerged as an important tool to analyze the functional impact of the variants 
[89]. 
Some approaches revealed that functional TFBSs can be considered as the 
on/off switches for gene transcription, so the alterations in these factors can lead to an 
alteration in gene expression, leading to a human disease [90].  
Also, mutations in exonic splicing enhancers (ESE) and exonic splicing 
silencers (ESS) may deregulate splicing machinery [83]. Importantly, approximately 
15% of mutations that cause genetic disease affect pre-mRNA splicing. In addition, 
synonymous coding SNPs can disrupt (or eventually create) ESEs and ESSs; create 
new splice sites or reinforce cryptic ones; alter pre-mRNA secondary structures; and, 
possibly cause changes in RNA Polymerase II [91]. 
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Figure 9: Regulation of gene expression mediated by miRNA: A) V30M allele with a polymorphism in 3’ UTR; B) V30M 
allele with WT 3’UTR. 
Additionally, miRNAs are being intensively studied in another 
neurodegenerative diseases [92], [93], [94], [95] have been the focus of many studies  
since it has been thought that SNPs in the 3’ UTR may disrupt the miRNA-mRNA 
interaction or create a new target site for a miRNA, leading to the alteration of the 
expression of target gene (Figure 9) [96]. In FAP ATTRV30M, the presence of miRNA 
target sites in 3’UTR of TTR gene had already been studied [97], [98], but the results 
are still not evident. 
All these studies reinforce the importance of the in silico analyses carried out in 
this study that was validated using different softwares, since the usage of these 
programs should be done with a critical view, because they can present different 
results from each other according to the algorithms and the thresholds used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3. Interaction between genes 
 
Furthermore, we also performed a MDR analysis for detection of gene-gene 
interactions, which is a powerful statistical tool of multilocus data reduction to improve 
the detection of genotypic combinations, in order to predict disease risk [99]. 
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Figure 10:  Structure and assembly of C1q. 
MDR studies are very important since we can detect high-order interaction even 
in the absence of statistically significant results and in small sample sizes. Additionally, 
combination of cross-validation a d per utati n testing diminishes the presence of 
false positive results.  So, this study gives us confidence in our results and allows us to 
find highly significant interaction between SNPs which may act together in the 
modulation of AO variability FAP ATTRV30M patients [100].  
We conclude that there is a strong interaction between C1QA and C1QC genes. 
This fact can be confirmed by the C1Q molecule structure and the three polypeptide 
chains, A, B and C, are the product of three distinct genes organized to form 6 triple 
helical strands (Figure 10). Chains A and B form a dimer through formation of disulfide 
bridges between the half-cysteine residues located at A-4 and B-4, whereas the C 
chain forms a disulfide-linked with the C chain of the next strand through cysteine 
residues found at position C-4. Posteriorly, the two dimer strands form a doublet, and 
three doublets are linked by non-covalent forces [101]. Therefore, each A-B dimer 
associates non-covalently with a C-chain to form a heterotrimeric collagen-like triple 
helix [102]. These data shows the molecular interaction between C1QA and C1QC 
reinforcing our statistical findings and showing that these two genes may act together 
as genetic modifiers. 
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In addition, we performed a MDR analysis for detection of C1QA-C1QC-RAC1 
interactions, and we conclude that RAC1 gene do not interact neither with C1QA gene 
nor with C1QC gene. 
We have to pay attention for the possibility of other genes and other SNPs 
within these genes being associated with AO variability in FAP ATTRV30M. But 
importantly, our study revealed several strengths: a large sample size for a rare 
disease and a family centered approach which prevents population stratification, as 
opposed to case-control study [103]; the use of GEE analysis, since corrects for familial 
correlations of AO and it allows a greater power to detect a statistically significant effect 
[104]; the inclusion of multiple testing corrections to avoid errors type I [105]; and 
finally, the clinical observation of all patients by the same team of neurologists, 
minimizing differences in the establishment of AO.  
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6. CONCLUSIONS 
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This study aimed to identify possible genetic modifiers associated to FAP 
ATTRV30M pathways, in order to assess their involvement in AO variability. After 
genotyping a large number of individuals, we found a significant association of some 
variants in candidate genes with AO variability. 
 
Concerning RAC1 gene: 
 We found five significant SNPs associated with an earlier onset and two SNPs 
associated with a later onset in FAP ATTRV30M.  
 rs3729790 may alter the binding to the IRF-7 factor, increasing the 
transcriptional levels, and it may act as a risk factor in FAP ATTRV30M 
carriers. On the other hand, rs702483 may change the consensus motif of the 
Evi-1 factor, which may cause a downregulation of RAC1 expression, so it may 
act as a protective factor in FAP ATTRV30M disease.  
 miRNAs also seem interfere with the putative binding of target sites:  the hsa-
miR-4539 related with rs9374 (LDsnp rs3729790) and the hsa-miR-4773 
related with rs6951997 (LDsnp rs3729796). 
 Although there is no statistical evidence regarding association with AO to 
support the results obtained by in silico analysis, our results open new 
perspectives that deserve to be further explored since new disease targets can 
be unraveled. 
 
Regarding complement C1Q genes: 
 For C1QA gene we found two SNPs associated with a late-onset, and for C1QC 
gene three SNP associated with an early-onset, and one SNP was associated 
with a late-onset. 
 For C1QA gene we found that rs172378 was implicated in the inactivation of an 
acceptor site and branch point site. On the contrary, the analysis of 
rs201693493 showed the creation of a new splice site, with probability to alter 
splicing activity in this gene. 
 For C1QC we can conclude that two variants (rs2935537 and rs294180 (LDsnp 
9434)) caused alterations in the NERF1a and CAT8 TFBs, respectively. The 
first one contribute to the decrease of transcriptional levels and it plays a 
possible risk factor for the FAP ATTRV30M patients, while the second was 
involved in expression of a large number of genes required for metabolism of 
nonfermentable carbon sources.  
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With this study, we confirmed the role of C1Q complement genes in FAP 
ATTRV30M Portuguese patients and we revealed, for the first time, the role of RAC1 
gene as a genetic modifier of AO variability. Importantly, we found very interesting and 
unreported results in the in silico analysis since alterations in these mechanisms can 
lead to dysregulation of gene expression, which can have an impact in AO and 
phenotypic variability. 
We concluded that there is a strong interaction between C1QA and C1QC 
genes showing that these two genes may act together as genetic modifiers. 
In conclusion, our results are important to understand the differences in AO 
between members of the same family unraveling disease mechanisms which may have 
implications in genetic counselling and in the discovery of new biomarkers.  
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7. FUTURE PERSPECTIVES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 49 
 
FCUP 
Unravelling modulators of age-at-onset variability in FAP ATTRV30M 
 
 
Unravelling modulators of age-at-onset variability in FAP ATTRV30M   
 
As futures perspectives we intend to: 
 
 Increase our sample to draw conclusions about the impact of rare 
polymorphisms in AO variation in FAP ATTRV30M. 
 Study the genetic interaction of RAC1 gene with TTR to further explore the 
results found in Drosophila models. 
 Confirm in vivo studies if the presence of the new TFBs (IRF-1 and Evi-1) found 
in the RAC1 gene have a significant impact on disease progression. 
 Study the possible presence of rs9374 (LDsnp rs3729790) and rs6951997 
(LDsnp rs3729796)  in a larger number of FAP ATTRV30M carriers and study 
the association of the putative target site for hsa-mir-4539 and hsa-mir-4773 
(respectively) with the phenotype; 
 Apply the information about C1QA mRNA splicing alterations in therapeutics, 
like antisense oligonucleotides; 
 Perform a SNP profile for RAC1, C1QA and C1QC genes in livers of patients 
already transplanted to understand the differences in disease progression found 
in these patients; 
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Annex 1 
 
Table 13: Primers sequence (Forward and Reverse) of each exon of each gene. 
Genes Exons Primers Sequences 
 
 
 
 
 
 
RAC1 
Exon 1 Primer Forward TGCAGTTTTCCTCAGCTTTG 
Exon 1 Primer Reverse AGGGGATCGAGAGGTTCATG 
Exon 2 Primer Forward TGCTAAGTATGTGATGTATATGCC 
Exon 2 Primer Reverse GTTCATATGAGGATTAAAGATGGC 
Exon 3 Primer Forward TTCTTGGCACACCTTCTCTAGG 
Exon 3 Primer Reverse AATGATGGCAATATAAGCAAGTCC 
Exon 4 Primer Forward GTGTTTCAGTGGCATTTGTCATC 
Exon 4 Primer Reverse GCAAAACCCCAACCTTGAGTG 
Exon 5 Primer Forward TCTGACCACACCACTGGTAGAC 
Exon 5 Primer Reverse GGCTACAGTGAGCTCTGATGTC 
Exon 6 Primer Forward GAGGTTAGGTGTCTGGCATGAG 
Exon 6 Primer Reverse GACCCCACTCTCTTCTGATCACAC 
Exon 7 Primer Forward GATAAAGACACGATCGAGAAACTG 
Exon 7 Primer Reverse AATTACTGATTGGTTCAAAAAATGG 
 
 
C1QA 
Exon 2 Primer Forward TATCATTGTGTGCATGGGACTC 
Exon 2 Primer Reverse ACAAACTGGAGAGGATTCATGG 
Exon 3.1 Primer Forward TTCATTGCCCTTTATCCCATAG 
Exon 3.1 Primer Reverse CCTGGAAGGTGAAGTAGTAGTAGCC 
Exon 3.2 Primer Forward ACACGGTCATCACCAACCAG 
Exon 3.2 Primer Reverse TCAGCAGACACAGACACAGATG 
 
 
C1QC 
Exon 2 Primer Forward GAAGAAAAGGCCCCACCATC 
Exon 2 Primer Reverse CCAGACACACCGTGAGAGTCC 
Exon 3.1 Primer Forward CCTAGGGAGATAGCCCATCTATGAG 
Exon 3.1 Primer Reverse ATGCCCACCATGTCGTAGTAGTC 
Exon 3.2 Primer Forward CCAAAACCAATCAGGTCAACTC 
Exon 3.2 Primer Reverse AGGAAGGAGAGAACCCATGG 
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Table 14: PCR Protocol for RAC1 (Exon 1). 
Reagents Volume per sample 
DMSO 0.60 µL 
HotStar Master Mix (Qiagen) 3.15 µL 
Primer Fw  10µM 0.75 µL 
Primer Rw  10µM 0.75 µL 
DNA (10 ng) 1 µL 
Total 6.25 µL 
 
Table 15: PCR Protocol for RAC1 (Exon 2-7), C1QA and C1QC. 
Reagents Volume per sample 
H2O 1.12 µL 
HotStar Master Mix (Qiagen) 3.13 µL 
Primer Fw  10µM 0.5 µL 
Primer Rw  10µM 0.5 µL 
DNA (10 ng) 1 µL 
Total 6.25 µL 
 
 
 
 
 
*We use 58oC for exon 2 of RAC1 and the remaining exons were amplified at 61oC. 
Table 16: Conditions of PCR protocol for RAC1 gene (Exon 1). 
Number of Cycles Temperature Time Phases 
1 95
o
C 15 min Initial Denaturation 
 
35 
95
o
C 45 sec Denaturation 
59ºC 1 min 30 sec Annealing 
72
o
C 1 min Extension 
1 72
o
C 10 min Final Extension 
- 15
o
C ∞ - 
Table 17: Conditions of PCR protocol for RAC1 (Exon 2-7). 
Number of Cycles Temperature Time Phases 
1 95
o
C 15 min Initial Denaturation 
 
30 
95
o
C 45 sec Denaturation 
58/61
o
C * 1 min Annealing 
72
o
C 1 min Extension 
1 72
o
C 10 min Final Extension 
- 15
o
C ∞  
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* We use 61oC for exon 2 and exon 3.1 and for exon 3.2 we use 63ºC. 
 
 
 
 
 
 
Table 18: Conditions of PCR protocol for C1QA gene. 
Number of Cycles Temperatur  Time hases 
1 95
o
C 15 min Initial Denaturation 
 
30 
95
o
C 45 sec Denaturation 
61
o
C 1 min Annealing 
72
o
C 1 min Extension 
1 72
o
C 10 min Final Extension 
- 15
o
C ∞  
Table 19: Conditions of PCR protocol for C1QC gene. 
Number of Cycles Temperature Time Phases 
1 95
o
C 15 min Initial Denaturation 
 
30 
95
o
C 45 sec Denaturation 
61/63
o
C * 1 min Annealing 
72
o
C 1 min Extension 
1 72
o
C 10 min Final Extension 
- 15
o
C ∞  
Table 20: Protocol for PCR products purification (RAC1, C1QA and C1QC). 
Reagents Volume per sample 
PCR product 2 µL 
Exostar 0.5 µL 
Total 2.5 µL 
Table 21: Conditions for PCR products purification (RAC1, C1QA and C1QC). 
Temperature Time Phases 
37
o
C 15 min Enzymatic Digestion 
85
o
C 15 min Enzymatic Inactivation 
15
o
C ∞  
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Table 22: Sequencing protocol for three genes (RAC1, C1QA and C1QC). 
Reagents Volume per sample 
 Purified PCR product 2.5 µL 
H2O 5.0 µL 
Primer (Fw/Rv) 0.5  µL 
BigDye ® Terminator v1.1 – 1:1 2.0  µL 
Total 10 µL 
Table 23: Conditions for sequencing protocol for three genes (RAC1, C1QA and C1QC). 
Number of Cycles Temperature Time Phases 
1 95
o
C 5 min Initial Denaturation 
 
35 
96
o
C 10 sec Denaturation 
50
o
C 5 sec Annealing 
60
o
C 4 min Extension 
- 15
o
C ∞  
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Annex 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
rs200222012 rs749782387 rs144425992 
rs144607000 
rs3729789 rs200639704 rs762492724 
Figure 11: Statistically significant variants for RAC1 gene. 
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rs2935537 rs201241346 
rs201693493 rs149050968 
rs200952686 
Figure 12: Variants statistically significant for C1QA gene. 
Figure 13: Variants statistically significant for C1QC gene. 
